An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2016
At a glance
- Drugs Navitoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors AbbVie
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Mar 2013 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 12 Mar 2013 New trial record